ELOXX PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $2.00 thousand for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-09-11
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.00K S-1 · filed 2026-09-11 | $2.00M 10-K · filed 2026-03-17 |
| 2024-12-31 | $19.00K S-1 · filed 2026-09-11 | $19.00M 10-K · filed 2026-03-17 |
| 2023-12-31 | $322.00K S-1 · filed 2026-09-11 | $322.00M 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |